112 related articles for article (PubMed ID: 32620617)
1. Pan- and Isoform-specific Inhibition of the Bromodomain and Extra-terminal Proteins and Evaluation of Synergistic Potential With Entospletinib in Canine Lymphoma.
Kong W; Sender S; Perez SV; Sekora A; Ruetgen B; Junghanss C; Nolte I; Murua Escobar H
Anticancer Res; 2020 Jul; 40(7):3781-3792. PubMed ID: 32620617
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the Synergistic Potential of Simultaneous Pan- or Isoform-Specific BET and SYK Inhibition in B-Cell Lymphoma: An In Vitro Approach.
Sender S; Sultan AW; Palmer D; Koczan D; Sekora A; Beck J; Schuetz E; Taher L; Brenig B; Fuellen G; Junghanss C; Murua Escobar H
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230614
[No Abstract] [Full Text] [Related]
3. Precursor B-ALL Cell Lines Differentially Respond to SYK Inhibition by Entospletinib.
Sender S; Sekora A; Villa Perez S; Chabanovska O; Becker A; Ngezahayo A; Junghanss C; Murua Escobar H
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435587
[TBL] [Abstract][Full Text] [Related]
4. An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma.
Burke JM; Shustov A; Essell J; Patel-Donnelly D; Yang J; Chen R; Ye W; Shi W; Assouline S; Sharman J
Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):e327-e331. PubMed ID: 29934062
[TBL] [Abstract][Full Text] [Related]
5. NF-κB signaling activation via increases in BRD2 and BRD4 confers resistance to the bromodomain inhibitor I-BET151 in U937 cells.
Hishiki K; Akiyama M; Kanegae Y; Ozaki K; Ohta M; Tsuchitani E; Kaito K; Yamada H
Leuk Res; 2018 Nov; 74():57-63. PubMed ID: 30300821
[TBL] [Abstract][Full Text] [Related]
6. Dual targeting of bromodomain-containing 4 by AZD5153 and BCL2 by AZD4320 against B-cell lymphomas concomitantly overexpressing c-MYC and BCL2.
Takimoto-Shimomura T; Tsukamoto T; Maegawa S; Fujibayashi Y; Matsumura-Kimoto Y; Mizuno Y; Chinen Y; Shimura Y; Mizutani S; Horiike S; Taniwaki M; Kobayashi T; Kuroda J
Invest New Drugs; 2019 Apr; 37(2):210-222. PubMed ID: 29931583
[TBL] [Abstract][Full Text] [Related]
7. Scaffold hopping of the SYK inhibitor entospletinib leads to broader targeting of the BCR signalosome.
Jorda R; Krajčovičová S; Králová P; Soural M; Kryštof V
Eur J Med Chem; 2020 Oct; 204():112636. PubMed ID: 32731189
[TBL] [Abstract][Full Text] [Related]
8. The bromodomain protein inhibitor I-BET151 suppresses expression of inflammatory genes and matrix degrading enzymes in rheumatoid arthritis synovial fibroblasts.
Klein K; Kabala PA; Grabiec AM; Gay RE; Kolling C; Lin LL; Gay S; Tak PP; Prinjha RK; Ospelt C; Reedquist KA
Ann Rheum Dis; 2016 Feb; 75(2):422-9. PubMed ID: 25467295
[TBL] [Abstract][Full Text] [Related]
9. AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies.
Rhyasen GW; Hattersley MM; Yao Y; Dulak A; Wang W; Petteruti P; Dale IL; Boiko S; Cheung T; Zhang J; Wen S; Castriotta L; Lawson D; Collins M; Bao L; Ahdesmaki MJ; Walker G; O'Connor G; Yeh TC; Rabow AA; Dry JR; Reimer C; Lyne P; Mills GB; Fawell SE; Waring MJ; Zinda M; Clark E; Chen H
Mol Cancer Ther; 2016 Nov; 15(11):2563-2574. PubMed ID: 27573426
[TBL] [Abstract][Full Text] [Related]
10. BTK and PI3K Inhibitors Reveal Synergistic Inhibitory Anti-Tumoral Effects in Canine Diffuse Large B-Cell Lymphoma Cells.
Kong W; Sender S; Taher L; Villa-Perez S; Ma Y; Sekora A; Ruetgen BC; Brenig B; Beck J; Schuetz E; Junghanss C; Nolte I; Murua Escobar H
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884478
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of SYK or BTK augments venetoclax sensitivity in SHP1-negative/BCL-2-positive diffuse large B-cell lymphoma.
Sasi BK; Martines C; Xerxa E; Porro F; Kalkan H; Fazio R; Turkalj S; Bojnik E; Pyrzynska B; Stachura J; Zerrouqi A; Bobrowicz M; Winiarska M; Priebe V; Bertoni F; Mansouri L; Rosenquist R; Efremov DG
Leukemia; 2019 Oct; 33(10):2416-2428. PubMed ID: 30872780
[TBL] [Abstract][Full Text] [Related]
12. AZD5153, a novel BRD4 inhibitor, suppresses human thyroid carcinoma cell growth in vitro and in vivo.
Xu K; Chen D; Qian D; Zhang S; Zhang Y; Guo S; Ma Z; Wang S
Biochem Biophys Res Commun; 2018 May; 499(3):531-537. PubMed ID: 29596834
[TBL] [Abstract][Full Text] [Related]
13. AZD5153 Inhibits Prostate Cancer Cell Growth in Vitro and in Vivo.
Shen G; Chen J; Zhou Y; Wang Z; Ma Z; Xu C; Jiang M
Cell Physiol Biochem; 2018; 50(2):798-809. PubMed ID: 30308485
[TBL] [Abstract][Full Text] [Related]
14. Dissecting the Role of BET Bromodomain Proteins BRD2 and BRD4 in Human NK Cell Function.
Cribbs AP; Filippakopoulos P; Philpott M; Wells G; Penn H; Oerum H; Valge-Archer V; Feldmann M; Oppermann U
Front Immunol; 2021; 12():626255. PubMed ID: 33717143
[TBL] [Abstract][Full Text] [Related]
15. SYK Targeting Represents a Potential Therapeutic Option for Relapsed Resistant Pediatric
Serafin V; Porcù E; Cortese G; Mariotto E; Veltri G; Bresolin S; Basso G; Accordi B
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31817853
[TBL] [Abstract][Full Text] [Related]
16. BET inhibition targets ABC-DLBCL constitutive B-cell receptor signaling through PAX5.
Oien DB; Sharma S; Hattersley MM; DuPont M; Criscione SW; Prickett L; Goeppert AU; Drew L; Yao Y; Zhang J; Chan HM
Blood Adv; 2023 Sep; 7(17):5108-5121. PubMed ID: 37184294
[TBL] [Abstract][Full Text] [Related]
17. SYK inhibition and response prediction in diffuse large B-cell lymphoma.
Cheng S; Coffey G; Zhang XH; Shaknovich R; Song Z; Lu P; Pandey A; Melnick AM; Sinha U; Wang YL
Blood; 2011 Dec; 118(24):6342-52. PubMed ID: 22025527
[TBL] [Abstract][Full Text] [Related]
18. An open-label phase 2 trial of entospletinib in indolent non-Hodgkin lymphoma and mantle cell lymphoma.
Andorsky DJ; Kolibaba KS; Assouline S; Forero-Torres A; Jones V; Klein LM; Patel-Donnelly D; Smith M; Ye W; Shi W; Yasenchak CA; Sharman JP
Br J Haematol; 2019 Jan; 184(2):215-222. PubMed ID: 30183069
[TBL] [Abstract][Full Text] [Related]
19. Second-Generation SYK Inhibitor Entospletinib Ameliorates Fully Established Inflammation and Bone Destruction in the Cherubism Mouse Model.
Yoshimoto T; Hayashi T; Kondo T; Kittaka M; Reichenberger EJ; Ueki Y
J Bone Miner Res; 2018 Aug; 33(8):1513-1519. PubMed ID: 29669173
[TBL] [Abstract][Full Text] [Related]
20. Bromodomain and Extra-terminal (BET) Protein Inhibitors Suppress Chondrocyte Differentiation and Restrain Bone Growth.
Niu N; Shao R; Yan G; Zou W
J Biol Chem; 2016 Dec; 291(52):26647-26657. PubMed ID: 27821592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
